N
Nicholas Obermüller
Researcher at Goethe University Frankfurt
Publications - 35
Citations - 1378
Nicholas Obermüller is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Kidney & Acute kidney injury. The author has an hindex of 17, co-authored 34 publications receiving 1239 citations.
Papers
More filters
Journal ArticleDOI
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy
Edgar A. Otto,Toby W. Hurd,Rannar Airik,Moumita Chaki,Weibin Zhou,Corinne Stoetzel,Suresh B. Patil,Shawn Levy,Amiya K. Ghosh,Carlos Murga-Zamalloa,Jeroen van Reeuwijk,Stef J.F. Letteboer,Liyun Sang,Rachel H. Giles,Qin Liu,Karlien L.M. Coene,Alejandro Estrada-Cuzcano,Rob W.J. Collin,Heather M. McLaughlin,Susanne Held,Jennifer M. Kasanuki,Gokul Ramaswami,Jinny Conte,Irma Lopez,Joseph Washburn,James W. MacDonald,Jinghua Hu,Yukiko M. Yamashita,Eamonn R. Maher,Lisa M. Guay-Woodford,Hartmut P. H. Neumann,Nicholas Obermüller,Robert K. Koenekoop,Carsten Bergmann,Xiaoshu Bei,Richard A. Lewis,Nicholas Katsanis,Vanda S. Lopes,David S. Williams,Robert H. Lyons,Chi V. Dang,Daniela A Brito,Mónica Bettencourt Dias,Xinmin Zhang,James D. Cavalcoli,Gudrun Nürnberg,Peter Nürnberg,Eric A. Pierce,Peter K. Jackson,Corinne Antignac,Sophie Saunier,Ronald Roepman,Hélène Dollfus,Hemant Khanna,Friedhelm Hildebrandt +54 more
TL;DR: This work identifies loss of SDCCAG8 function as a cause of a retinal-renal ciliopathy and validates exome capture analysis for broadly heterogeneous single-gene disorders.
Journal ArticleDOI
Biomarkers of kidney injury
TL;DR: In clinical settings with incipient AKI, not only the development and the implementation of more sensitive biomarkers are required for earlier treatment initiation in order to attenuate the severity of kidney injury, but also equally important remains the substantial improvement and application of refined and prophylactic therapeutic options.
Journal ArticleDOI
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Paul Gutwein,Anja Schramme,Nina Sinke,Mohamed S. Abdel-Bakky,Beren Voss,Nicholas Obermüller,Kai Doberstein,Michael Koziolek,Florian R. Fritzsche,Manfred Johannsen,Klaus Jung,Helmut Schaider,Peter Altevogt,Andreas Ludwig,Josef Pfeilschifter,Glen Kristiansen +15 more
TL;DR: The data demonstrate that downregulation of CXCL16 plays an important role in renal cancer development and progression, and that CxCL16 in RCC is an independent prognostic marker for better patient survival.
Journal ArticleDOI
Current developments in early diagnosis of acute kidney injury.
TL;DR: This work aimed to review novel biomarkers of AKI in urine and serum which have now progressed to the clinical phase and represent promising new markers that need to be further evaluated in the clinical setting for suitability.
Journal ArticleDOI
CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.
Paul Gutwein,Mohamed S. Abdel-Bakky,Anja Schramme,Kai Doberstein,Nicole Kämpfer-Kolb,Kerstin Amann,Ingeborg A. Hauser,Nicholas Obermüller,Christine Bartel,Abdel-Aziz H. Abdel-Aziz,El Sayed M. El Sayed,Josef Pfeilschifter +11 more
TL;DR: It is demonstrated that CXCL16 and ADAM10 are constitutively expressed in human podocytes in normal renal tissue, suggesting these proteins as new therapeutic targets in this glomerular kidney disease.